Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05684692 · ClinicalTrials.gov registry record · Phase 2
Screening Trial for Pain Relief in Schwannomatosis (STARFISH)
A Phase 2 study of Pain, Chronic and Schwannomatosis, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05684692 is a Phase 2 study of Pain, Chronic and Schwannomatosis that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 40 participants, below the 721-participant average among 48 other Pain, Chronic trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05684692, a Phase 2 study of Pain, Chronic and Schwannomatosis, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a placebo-controlled, multi-arm phase II platform screening trial designed to test the safety, pain responses, and pharmacodynamic activity of multiple experimental therapies simultaneously in participants with moderate-to-severe pain due to schwannomatosis (SWN). This Master Study is being conducted as a platform that may allow participants with pain associated with schwannomatosis to receive a novel intervention throughout this study. Embedded within the Master Study are individual drug sub-studies: * Investigational Drug Sub-Study A: Siltuximab * Investigation Drug Sub-Study B: Erenumab-Aooe
Conditions Studied
Interventions
- DRUG Siltuximab
- DRUG Erenumab-Aooe
- DRUG Siltuximab Matching Placebo
- DRUG Erenumab-Aooe Matching Placebo
Study Locations (1)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-08-31 |
| Est. Completion | 2027-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05684692
The ClinicalTrials.gov registry entry for NCT05684692 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 721-participant average among 48 other Pain, Chronic trials with a reported enrollment target (94% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pain, Chronic appearing as the primary indexed condition, and to 4 interventions - of which Siltuximab is the first listed.
NCT05684692 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05684692 about?
NCT05684692 is a clinical study titled "Screening Trial for Pain Relief in Schwannomatosis (STARFISH)". This is a placebo-controlled, multi-arm phase II platform screening trial designed to test the safety, pain responses, and pharmacodynamic activity of multiple experimental therapies simultaneously in participants with moderate-to-severe pain due to schwannomatosis (SWN). This Master Study is being...
What is the current status of trial NCT05684692?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2023-08-31. Estimated completion is 2027-11-30.
What conditions does trial NCT05684692 study?
This clinical trial studies the following conditions: Pain, Chronic, Schwannomatosis, Schwannomas.
What interventions are being tested in trial NCT05684692?
The interventions under investigation include: Siltuximab (DRUG), Erenumab-Aooe (DRUG), Siltuximab Matching Placebo (DRUG), Erenumab-Aooe Matching Placebo (DRUG).
Who is sponsoring clinical trial NCT05684692?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05684692 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pain Reprocessing Therapy in Post-Operative Knee Pain
RECRUITING · Phase 2
-
Prescription Opioids, Brain Structure, and Cognition in Older Adults With Chronic Pain
RECRUITING · Phase 2
-
MIVetsCan: Cannabidiol (CBD)-Care Trial
RECRUITING · Phase 2
-
Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure
ACTIVE NOT RECRUITING · Phase 2
-
RTMS for Treatment of Pain and Craving
COMPLETED · Phase 2
-
Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.